Ecoland International, Inc. (ECIT) awarded new contract, shares rise
Posted on: December 5th, 2011Written by:
Shares of Ecoland International, Inc. (OTCBB: ECIT) climbed 16 percent on Moncontract from Johnson Controls on Monday after the Arizona-based company announced that it was awarded a contract from Johnson Controls (NYSE: JCI) exceeding $1.2 million, to be delivered over the next four months.
ECIT shares touched a high of $0.43 in morning trading on Monday, up from Friday’s closing price of $0.37.
According to a December 5 press release, the newly awarded project “signals the beginning of the second phase of Johnson Controls’ production relocation project,” which Ecoland’s subsidiary, D&R Technology has participated and “played an important role in for the last twelve months.”
The project “demonstrates the success of our business strategy and the confidence of our customer in our ability,” said D&R’s president Drasko Karanovic in the December 5 press release. “It is flattering to be one of the companies that helped Johnson Controls’ achieve best ever financial results for the past year. Our objective for the next period is to maintain and further develop this mutually beneficial relationship. Johnson Controls is world’s market leader in automotive seating with about 45% of the market. We see tremendous potential for our growth by simply satisfying their needs in the global market.”
For the three months ended August 31, Ecoland reported sales of $3,376, and a net loss of $47,730.
In early November, the company announced that it closed the acquisition of D&R Technology, Inc. Pursuant to the share exchange agreement, D&R’s shareholders will receive a majority share ownership in ECIT and it is anticipated that a name change will be made reflecting this change in majority share ownership. Also, according to the share exchange agreement, D&R’s management team will assume operational and managerial control effective immediately, a November 7 press release stated.
D & R Technology Inc. provides engineering, design and the manufacturing of automated tube processing solutions for the automotive industry.
Arrowhead Research Corp. (ARWR) soars on news of positive data from weight loss drug
Posted on: November 10th, 2011Written by:
Nanomedicine company, Arrowhead Research Corp. (Nasdaq: ARWR) announced on Thursday that data from its subsidiary’s obesity drug demonstrated weight loss, reduction in body mass index and abdominal circumference in obese rhesus monkeys.
The data, which was published in Science Translational Medicine (Sci Trans Med 3, 108ra112 (2011) DOI: 10.1126/scitraslmed-3002621), demonstrates that monkeys treated with Adipotide lost an average of 11 percent of their body weight after only four weeks of treatment.
Adipotide-treated animals also showed marked improvements in insulin resistance, suggesting the potential for use in treating type-2 diabetes.
Shares of the Pasadena-based Arrowhead Research Corp. touched a new 52-week high of $1.19 on Thursday, up 120 percent from Wednesday’s c losing price of $0.54.
“Safely and effectively treating the obesity epidemic is one of the great unmet needs in medicine today,” said Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead in a November 10 press release. “This study is a radical step forward for both Ablaris’ technology and the treatment of obesity.It is uncommon for an obesity treatment to be successfully translated from rodent studies to non-human primates. Ablaris’ approach is distinguished from others in the field by its unique mode of action. By acting directly on the vasculature that supports fat tissue rather than on the brain, we believe that we can avoid many of the safety issues that have blocked other anti-obesity drug candidates. We are extremely encouraged by the results achieved to date with Adipotide and believe that Ablaris’ unique technology offers a significant advantage to combating obesity as we prepare to enter the clinic in the near-term.”
Perma-Fix Environmental Services, Inc. (PESI) reports record Q3 revenue
Posted on: November 3rd, 2011Written by:
Waste management and engineering services company Perma-Fix Environmental Services, Inc. (Nasdaq: PESI) reported record third quarter revenue thanks in large part to increased treatment of higher activity and more complex waste streams.
The Atlanta-based company reported third quarter revenue of $32.8 million, a 43 percent increase over revenue of $22.9 million in the same period last year. Revenue for the Nuclear Segment increased 44.0% to $32.1 million from $22.3 million for the same period in 2010. Revenue generated from the DOE Hanford Site increased approximately $787,000 for the quarter while $9.0 million was derived from an increase in waste processed at our treatment facilities. Revenue from the Engineering Segment increased to $701,000 from $581,000 for the same period in 2010.
Net income for the third quarter of 2011 increased to $6.0 million, or $0.11 per share, versus a net loss of $1.1 million or $0.02 per share, for the same period in 2010. Net income for the third quarter of 2011 included a gain on the sale of PFFL of approximately $1.8 million, partially offset by a loss from discontinued operations of $187,000.
“The second half of 2011 is proving to be one of the strongest periods in our history and we believe this demonstrates that our strategy is working,” said Perma-Fix Environmental Services’ chairman and CEO, Dr. Louis F. Centofanti in a November 3 press release.
“We also improved our balance sheet during the quarter. As a result of our strong cash flow, coupled with the recent sale of Fort Lauderdale facility, we had over $10.7 million of cash and just $5.7 million of total debt at the end of the third quarter.”
Positron Corp. (POSC) soars on news of $38 million bonds award
Posted on: September 21st, 2011Written by:
Molecular imaging company, Positron Corp. (OTCBB: POSC) was up more than 49 percent in mid-day trading on Wednesday, after the company announced that the Indiana Finance Authority approved its $38 million Midwestern Disaster Area Bond volume cap application.
Shares of Positron touched a daily high of $0.029, in mid-day trading on Wednesday, up from Tuesday’s closing price of $0.0181.
According to a September 21 press release, the bonds will be a part of an overall long-term strategic investment Positron is making in its proposed high energy 70 MeV cyclotron project and radiopharmaceutical manufacturing facility in Noblesville, Indiana.
Positron is a molecular imaging company focused on Nuclear Cardiology. Positron provides innovative molecular technologies and services that are reshaping the field of nuclear cardiology through proprietary PET imaging and radiopharmaceutical solutions with a strong commitment to advancing the practice and technology of nuclear medicine.
Caduceus Software Systems Corp. (CSOC) soars on pricey marketing campaign
Posted on: September 19th, 2011Written by:
Software medical records management software developer, Caduceus Software Systems Corp. (OTCBB:CSOC) traded more than 16 million shares on Monday, a far cry from the company’s average three-month volume of 49,478 shares, after the onset of a $1 million-plus e-mail campaign spearheaded by VictoryStocks.com.
The campaign was paid for by a third party, listed as “Firdaus Inc.”
The last time Caduceus Software Systems Corp. issued a press release was about a month ago, when the Birmingham, England-based company announced its goals and mission statement.
The Company has the primary goal of providing good valuable medical records management software (MMS) to medical professionals. The Company’s target market is to provide Electronic Health Records (EHR) management for practitioners and physicians, and combine it with the appointment scheduling tools useful for medical office assistants. While some software caters to specifically to doctors and some software caters specifically to their supporting staff, Caduceus MMS integrates these tasks together in a single software solution, the August 16 press release stated.
“The recent news of the American health care reform and the cost of health care in Canada and United States warrant better software to manage the flow of patient information and fast and accurate billing,” sais Derrick Gidden, President of Caduceus Software Systems Corp in the August 16 press release. “The Canadian and American markets are vast and total more than 800,000 private physicians and practitioners. From the news studies, we feel that many of these medical professionals could benefit from our software in terms of our price point, multiple languages, tech support, and platform compatibility requirements.”
For the three months ended June 30, Caduceus Software Systems Corp. reported $0 revenue, and a net loss of $4.9 million.
Location Based Technologies, Inc. (LBAS) soars on new Mexican contract
Posted on: August 30th, 2011Written by:
Location Based Technologies®, Inc. (OTCBB:LBAS) shares zoomed 6.9% to 83.4 cents late Monday, on news of a lucrative purchase order from Mexico. Volume for the stock totaled 1.2 million shares, surpassing a daily average of around 816,000.
A news release issued August 29 stated that the Irvine, Calif.-headquartered LBT, a leading-edge service provider of personal, pet and asset location devices, received a $1.2-million purchase order from Grupo Paramuen SA de C.V, a GPS solutions provider for the B2B mobile electronics market in Mexico. LBT will ship both the PocketFinder® Personal and Vehicle units to Grupo Paramuen before year end.
The release quoted LBT CEO Dave Morse as saying, “This purchase order establishes our initial push into the Latin American market. We are extremely excited about the opportunity that Mexico represents for us.”
Morse concluded, “We believe there is a tremendous need for our products and services in Mexico and South America, and partners like Grupo Paramuen will allow us to establish a significant presence abroad.”
Location Based Technologies®, Inc. designs and develops leading-edge personal locator devices and services that incorporate patented, proprietary technologies designed to enhance and enrich the way businesses and families interact globally.
